SCHEMBL22494673

SCHEMBL22494673

N#CN[C@H]1C[C@H](C(=O)Nc2ncc(-c3ccccc3)s2)C1

nearest known ligand 0.63

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ UCHL1 P09936 2/20 0.63
▸ USP30 Q70CQ3 8/20 0.61
▸ MKNK1 Q9BUB5 1/20 0.60
▸ KDR P35968 1/20 0.55
▸ GSTO1 P78417 1/20 0.52
▸ CCNE1 P24864 1/20 0.51
▸ CDK2 P24941 1/20 0.51
▸ CDK5 Q00535 1/20 0.51
▸ SCD O00767 1/20 0.51
▸ OTUD7B Q6GQQ9 2/20 0.49
▸ ACP1 P24666 1/20 0.49
▸ CNR1 P21554 1/20 0.48
▸ CNR2 P34972 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22494615 1.00 UCHL1 (0.63) UCHL1USP30MKNK1KDRGSTO1
SCHEMBL22494614 1.00 UCHL1 (0.63) UCHL1USP30MKNK1KDRGSTO1
SCHEMBL20883074 0.92 UCHL1 (0.62) UCHL1USP30MKNK1KDRGSTO1
SCHEMBL20883072 0.92 UCHL1 (0.62) UCHL1USP30MKNK1KDRGSTO1
SCHEMBL22494806 0.92 UCHL1 (0.62) UCHL1USP30MKNK1KDRGSTO1
SCHEMBL29146009 0.92 UCHL1 (0.62) UCHL1USP30MKNK1KDRGSTO1
SCHEMBL22494665 0.89 UCHL1 (0.52) UCHL1USP30MKNK1KDRGSTO1
SCHEMBL22494666 0.89 UCHL1 (0.52) UCHL1USP30MKNK1KDRGSTO1
SCHEMBL29377780 0.89 UCHL1 (0.52) UCHL1USP30MKNK1KDRGSTO1
SCHEMBL22523024 0.84 MKNK1 (0.67) UCHL1USP30MKNK1KDRGSTO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3692028-B1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS INC (US) 2023-04-26 — — EP claimed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 — — US claimed
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2020-10-08 — — US claimed
EP-3692028-B1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS INC (US) 2023-04-26 — — EP disclosed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 — — US disclosed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 — — US disclosed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 — — US disclosed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 — — US disclosed
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2020-10-08 — — US disclosed
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2020-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 UCHL1 2/4885USP30 1/4885MKNK1 1080/4885
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 USP30, UCHL1, UCHL3 UCHL1 2/4885USP30 1/4885MKNK1 2208/4885
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 UCHL1 2/4885USP30 1/4885MKNK1 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback